Navigation Links
Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
Date:10/14/2008

Company moves up Q3 earnings release date

NATICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today provided the following comments reinforcing the strength of its balance sheet:

The volatility of the financial markets and the Company's stock price volatility have had no noticeable effect on the financial strength or ongoing financial performance of the Company. Strong cash flow generation during the third quarter allowed the Company to prepay $500 million of debt obligations, reducing its debt position to approximately $6.8 billion. The next debt maturity of $825 million is not due until April 21, 2010, and continuing and improving strong operating cash flows are expected to more than adequately meet that obligation.

In the midst of very turbulent financial markets, the Company continues to manage its debt portfolio, cash investments, cash flow and working capital conservatively. The Company currently has access to approximately $3 billion of cash, with approximately $1.7 billion of cash on hand and access to approximately $1.3 billion of additional cash through its revolving bank credit facility. At the end of the second quarter, the Debt to EBITDA ratio under its credit facility was 2.8 to 1, and is expected to be largely unchanged at the end of the third quarter, well below its bank covenant requirement of 4.5 to 1. The Company continues to focus on lowering this ratio by improving operating cash flow and EBITDA, while paying down debt with available cash.

Rescheduled earnings call

The Company's third quarter earnings call was scheduled to take place at 8:00 a.m. ET on October 23rd. Since establishing this date and time, the Company became aware that
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LEXINGTON, Mass. , April 21, 2015 ... company developing transformative pharmaceutical products for subcutaneous ... its pivotal trial of its investigational proprietary ... treatment of edema associated with congestive heart ... development, scPharmaceuticals is developing a proprietary patch ...
(Date:4/21/2015)... Thornton Cleveleys (UK) (PRWEB) April 21, 2015 ... PEEK* technology and its clinical applications will ... Meeting. Participants include engineers, scientists, regulators and ... worldwide. The meeting is sponsored by Invibio ... PEEK polymer-based biomaterials, a specialist in manufacturing ...
(Date:4/20/2015)... MENLO PARK, Calif. , April 20, ... DMPI) (DelMar and the Company), a biopharmaceutical company ... in new orphan drug indications, today announced promising ... of the American Association for Cancer Research ... lead product candidate VAL-083 (dianhydrogalactitol) to ...
(Date:4/20/2015)... 2015  Eli Lilly and Company (NYSE: LLY ... cancer therapies, reflecting Lilly,s diverse oncology pipeline, during the ... held April 18-22 in Philadelphia , ... is the theme of this year,s AACR meeting and ... its portfolio of therapies that accelerate the pace and ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6
... RICHARDSON, Texas, Aug. 21 Zyvex Labs today ... company was started by Rob,Burgess, PhD, former Vice ... Gareth Hughes, PhD, former Group Leader of Life ... the application of nanotechnology in Life,Sciences. The company ...
... BOSTON and THE WOODLANDS, Texas, Aug. 21 ... presented data today,describing the structure-activity relationship (SAR) ... LX1031 and other compounds,under evaluation by the ... (IBS) and other gastrointestinal disorders. LX1031 is ...
... PITTSBURGH, Aug. 21 The Pittsburgh Life ... life,sciences industry on a fast track for growth, ... $450,000 in three companies: Applied Computational,Technologies, Separation Design ... to identifying and making investments in promising,life sciences ...
Cached Biology Technology:NanoMed, Inc. Spins Out of Zyvex Labs 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 2The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 3
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... the buzzword "nano" - cancer detection using nanoparticles and ... cancers is one of the most important parts of ... and determination,of the most appropriate treatment. And an essential ... there has been lymphatic spread. Current,methods include surgical removal ...
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... drugs that keep the HIV-virus infection from progressing to ... disturbances in some patients. The finding of a Mayo ... The Lancet. , In collaboration with colleagues from the ... University of Minnesota, Minneapolis, and University of Wisconsin, Madison, ...
Cached Biology News:Imaging Lymph Nodes with Nanoparticles 2GATA: a graphic alignment tool for comparative sequence analysis 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 3
Request Info...
Request Info...
Limit of detection: <5 pg/ml...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and Silencer Pre-designed siRNAs, ...
Biology Products: